SEARCH

SEARCH BY CITATION

References

  • Albasanz J. L., Dalfo E., Ferrer I. and Martin M. (2005) Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol. Dis. 20, 685693.
  • Ashley C. T., Jr, Wilkinson K. D., Reines D. and Warren S. T. (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262, 563566.
  • Auris Medical AG. (2008-[cited 2013 Sep 11) Efficacy of AM-111 in patients with acute sensorineural hearing loss. In: ClinicalTrials.gov [Internet], Bethesda, MD: National Library of Medicine (US). Available at: http://clinicaltrials.gov/ct2/show/NCT00802425 NLM identifier: NCT00802425.
  • Bai F. and Witzmann F. A. (2007) Synaptosome proteomics. Subcell. Biochem. 43, 7798.
  • Bear M. F., Huber K. M. and Warren S. T. (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370377.
  • Bingol B. and Sheng M. (2011) Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 69, 2232.
  • Bonny C., Oberson A., Negri S., Sauser C. and Schorderet D. F. (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50, 7782.
  • Borsello T., Clarke P. G., Hirt L., Vercelli A., Repici M., Schorderet D. F., Bogousslavsky J. and Bonny C. (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9, 11801186.
  • Brown V., Small K., Lakkis L., Feng Y., Gunter C., Wilkinson K. D. and Warren S. T. (1998) Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J. Biol. Chem. 273, 1552115527.
  • Celgene Corporation. (2010-[cited 2013 Sep 11) A study to characterize the safety, PK and biological activity of CC-930 in idiopathic pulmonary fibrosis (IPF). In: ClinicalTrials.gov [Internet], Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT01203943 NLM identifier: NCT01203943.
  • Celgene Corporation. (2011-[cited 2013 Sep 11) A research study to assess if CC-930 is safe in treating subjects with discoid lupus erythematosus. In: ClinicalTrials.gov [Internet], Bethesda, MD: National Library of Medicine (US). Available at: http://clinicaltrials.gov/ct2/show/NCT01466725 NLM identifier: NCT01466725.
  • Choi C. H., Schoenfeld B. P., Bell A. J. et al. (2011) Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res. 1380, 106119.
  • Darnell J. C. and Klann E. (2013) The translation of translational control by FMRP: therapeutic targets for FXS. Nat. Neurosci. 16, 17.
  • Darnell J. C., Van-Driesche S. J., Zhang C. et al. (2011) FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism. Cell 146, 247261.
  • Fu Y. H., Kuhl D. P., Pizzuti A. et al. (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67, 10471058.
  • Gallagher S. M., Daly C. A., Bear M. F. and Huber K. M. (2004) Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. J. Neurosci. 24, 48594864.
  • Gross C., Berry-Kravis E. M. and Bassell G. J. (2012) Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37, 178195.
  • Gump J. M. and Dowdy S. F. (2007) TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 13, 443448.
  • Hagerman P. J. (2008) The fragile X prevalence paradox. J. Med. Genet. 45, 498499.
  • Huber K. M., Kayser M. S. and Bear M. F. (2000) Role for Rapid dendritic protein synthesis in hippocampal mglur-dependent long-term depression. Science 288, 12541256.
  • Huber K. M., Gallagher S. M., Warren S. T. and Bear M. F. (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl Acad. Sci. USA 99, 77467750.
  • Jin P. and Warren S. T. (2000) Understanding the molecular basis of fragile X syndrome. Hum. Mol. Genet. 9, 901908.
  • Kremer E. J., Pritchard M., Lynch M. et al. (1991) Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 252, 17111714.
  • Krueger D. D. and Bear M. F. (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411429.
  • Lauterborn J. C., Rex C. S., Kramar E., Chen L. Y., Pandyarajan V., Lynch G. and Gall C. M. (2007) Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J. Neurosci. 27, 1068510694.
  • Malter J. S., Ray B. C., Westmark P. R. and Westmark C. J. (2010) Fragile X syndrome and Alzheimer's disease: another story about APP and beta-amyloid. Curr. Alzheimer Res. 7, 200206.
  • Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., Davis R. J., Shirasaki Y. and Greenberg M. E. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 75517560.
  • Muddashetty R. S., Kelic S., Gross C., Xu M. and Bassell G. J. (2007) Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J. Neurosci. 27, 53385348.
  • Muddashetty R. S., Nalavadi V. C., Gross C., Yao X., Xing L., Laur O., Warren S. T. and Bassell G. J. (2011) Reversible Inhibition of PSD-95 mRNA Translation by miR-125a, FMRP Phosphorylation, and mGluR Signaling. Mol. Cell 42, 673688.
  • Narayanan U., Nalavadi V., Nakamoto M., Pallas D. C., Ceman S., Bassell G. J. and Warren S. T. (2007) FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J. Neurosci. 27, 1434914357.
  • Narayanan U., Nalavadi V., Nakamoto M., Thomas G., Ceman S., Bassell G. J. and Warren S. T. (2008) S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J. Biol. Chem. 283, 1847818482.
  • Oka A. and Takashima S. (1999) The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol. 97, 275278.
  • Osterweil E. K., Krueger D. D., Reinhold K. and Bear M. F. (2010) Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 1561615627.
  • Park S., Park J. M., Kim S. et al. (2008) Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 59, 7083.
  • Patel M. R., Sadiq A. A., Jay-Dixon J., Jirakulaporn T., Jacobson B. A., Farassati F., Bitterman P. B. and Kratzke R. A. (2012) Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. Int. J. Oncol. 40, 577582.
  • Ploia C., Antoniou X., Sclip A. et al. (2011) JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. J. Alzheimer's Dis. 26, 315329.
  • Ronesi J. A. and Huber K. M. (2008a) Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J. Neurosci. 28, 543547.
  • Ronesi J. A. and Huber K. M. (2008b) Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci. Signal. 1, pe6.
  • Ronesi J. A., Collins K. A., Hays S. A. et al. (2012) Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat. Neurosci. 15, 431440.
  • Sabapathy K. (2012) Role of the JNK pathway in human diseases. Prog. Mol. Biol. Transl. Sci. 106, 145169.
  • Sclip A., Antoniou X., Colombo A. et al. (2011) c-Jun N-terminal kinase regulates soluble Abeta oligomers and cognitive impairment in AD mouse model. J. Biol. Chem. 286, 4387143880.
  • Shang Y., Wang H., Mercaldo V., Li X., Chen T. and Zhuo M. (2009) Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J. Neurochem. 111, 635646.
  • Sharma A., Hoeffer C. A., Takayasu Y., Miyawaki T., McBride S. M., Klann E. and Zukin R. S. (2010) Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694702.
  • Su T., Fan H. X., Jiang T., Sun W. W., Den W. Y., Gao M. M., Chen S. Q., Zhao Q. H. and Yi Y. H. (2011) Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology 215, 291300.
  • Thakur A., Wang X., Siedlak S. L., Perry G., Smith M. A. and Zhu X. (2007) c-Jun phosphorylation in Alzheimer disease. J. Neurosci. Res. 85, 16681673.
  • Tournier C., Whitmarsh A. J., Cavanagh J., Barrett T. and Davis R. J. (1997) Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. Proc. Natl Acad. Sci. USA 94, 73377342.
  • Waung M. W. and Huber K. M. (2009) Protein translation in synaptic plasticity: mGluR-LTD, Fragile X. Curr. Opin. Neurobiol. 19, 319326.
  • Westmark C. J. and Malter J. S. (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5, e52.
  • Westmark C. J., Westmark P. R. and Malter J. S. (2009) MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int. J. Clin. Exp. Pathol. 3, 5668.
  • Wilhelm M., Xu Z., Kukekov N. V., Gire S. and Greene L. A. (2007) Proapoptotic Nix Activates the JNK Pathway by Interacting with POSH and Mediates Death in a Parkinson Disease Model. J. Biol. Chem. 282, 12881295.
  • Wilhelm M., Kukekov N. V., Schmit T. L., Biagas K. V., Sproul A. A., Gire S., Maes M. E., Xu Z. and Greene L. A. (2012) Sh3rf2/POSHER protein promotes cell survival by ring-mediated proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty of SH3s) protein. J. Biol. Chem. 287, 22472256.
  • Xigen SA. (2012-[cited 2013 Sep 11) Safety, tolerability and PK of a single IV infusion of 10, 40, and 80 μg/kg XG-102 administered to healthy volunteers. In: ClinicalTrials.gov [Internet], Bethesda, MD: National Library of Medicine (US). Available at: http://clinicaltrials.gov/ct2/show/NCT01570205 NLM identifier: NCT01570205.
  • Yan Q. J., Rammal M., Tranfaglia M. and Bauchwitz R. P. (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 10531066.
  • Yang L., Mao L., Chen H., Catavsan M., Kozinn J., Arora A., Liu X. and Wang J. Q. (2006) A signaling mechanism from G{alpha}q-protein-coupled metabotropic glutamate receptors to gene expression: role of the c-Jun N-terminal kinase pathway. J. Neurosci. 26, 971980.
  • Yu S., Pritchard M., Kremer E. et al. (1991) Fragile X genotype characterized by an unstable region of DNA. Science 252, 11791181.